Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343101 | 0.94 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4630737 | 0.94 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4630727 | 0.92 | EDNRA (0.86) | EDNRAEDNRB | |
| SCHEMBL4632453 | 0.91 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL5210566 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6150988 | 0.89 | EDNRA (0.84) | EDNRAEDNRB | |
| SCHEMBL5215567 | 0.89 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL5211878 | 0.89 | EDNRA (0.83) | EDNRAEDNRB | |
| SCHEMBL434551 | 0.89 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL5206860 | 0.89 | EDNRA (1.00) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244657-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-27 | — | — | US | claimed |
| WO-2001049685-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| EP-1533311-B1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1533311-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1244657-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6686382-B2 | N-(ISOXAZOLYL)THIENYLSULFONAMIDES, N-(ISOXAZOLYL)FURYLSULFONAMIDES, N-(ISOXAZOLYL)PYRROLYLSULFONAMIDES AND N-(ISOXAZOLYL)PHENYLSULFONAMIDES; INHIBIT ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1244657-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-27 | — | — | US | disclosed |
| WO-2001049685-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.